Abstract Short-hairpinRNA(shRNA)-mediatedgeneknockdownisapowerfultoolfortargetedgene silencing and an emerging novel therapeutic strategy. Recent publications, however, reportedunexpectedtoxicityafterutilizingviral-mediatedshRNAknockdowninvivo.Thus,it iscurrentlyunclearwhethershRNA-mediatedknockdownstrategycanbeusedasasafeand efficient tool for gene silencing. In this study, we have generated rAAV vectors expressing shRNAstargetingtherattyrosinehydroxylase(TH)mRNA(shTH)fortestingtheefficacyofin vivo TH knockdown in the nigral dopaminergic neurons. At high titers, not only the shTH vectors but also the scrambled and green fluorescence protein (GFP)-only controls caused celldeath.Inadose-responsestudy,weidentifiedadosewindowleadingto>60%decrease in TH + neurons without any change in vesicular monoamine transporter-2 (VMAT2) expression. Moreover, using the safe and efficient dose, we showed that dopamine (DA) synthesisratewassignificantlyreducedandthisleadtoemergenceofmotordeficitsinthe shTH-expressing rats. Interestingly, these animals showed very robust and long-lasting recovery after a single systemic L-3,4-dihydroxyphenylalanine (L-DOPA) administration beyond what can be achieved in 6-hydroxydopamine (6-OHDA)-lesioned rats. Our results have implications for both mechanistic and therapeutic studies utilizing long-term shRNAmediatedgenesilencinginthenigrostriatalprojectionsystem.
givingriseto36%decreaseintheTHmRNAwhichledtobehavioralimpairmentin amphetamine-inducedlocomotoractivityandreducedperformanceintherotarodtest. 5 Anotherstudytargetingmutantataxin-1inatransgenicmousemodelofspinocerebellar ataxiatype1showedthatrAAV2-mediatedshRNAsilencingcanleadtosubstantialdecrease ofhumanataxin-1expressionresultinginmotorimprovementandnormalizedcerebellar pathology. 6 Later,intwoindependentstudies,lentiviralvectorswereutilizedtosilence superoxidedismutase(SOD1)expressioninatransgenicmousemodelofamyotrophic lateralsclerosisoverexpressingamutatedformofthehumanSOD1gene.Bothstudies demonstratedthatknockingdownSOD1bylentiviralshRNAsdelayedthedisease progressionandextendedthesurvivalofthemice.Inbothstudies,treatedmiceexhibiteda significantimprovementinmotorfunctionsupportingthetherapeuticpotentialofshRNA mediatedtargetedgenesilencing. 7, 8 Morerecently,however,theutilityofviralvector-mediatedshRNAsforinvivo targetedknockdownstudieshasbeenquestionedduetounexpectedtoxicityleadingtocell death.ByusingadoublestrandedrAAV8vector,Grimmandcolleaguesobservedliver damageandlethalityafterexpressionofshRNAstargetingthehumanα-1antitrypsinmRNA inatransgenicmouseline. 9 Theyfoundthattoxicitywasassociatedwithdownregulationof endogenousmiRNAs,whichcouldbeeliminatedbyreducingtheviraltiter.Thesefindings ledthemtoconcludethathighlevelsofshRNAexpressioncouldsaturatetheRNAipathway inthecellcausingunwantedsideeffectsandtoxicity.Ontheotherhand,striataltoxicity observedafterrAAV1shRNAdeliverytosilencethemutanthuntingtinexpressioninthe CAG140knock-inmousemodelofHuntington'sdiseasewasfoundnottoberelatedtothe saturationofthemiRNApathway. 10 Infact,thelatterstudyreportedthatalthoughthe dilutedvectorresultedinreducedtransductionefficiencyinthestriatum,itdidnotdecrease thetoxicity.Thus,itpresentlyremainsunclearwhetheradosewindowforviralvector mediatedshRNAexpressionthatdoesnotleadtonon-specifictoxicitybutmaintainshigh efficacyinvivointhebraincanbedefined. Results Inthisstudy,ouraimwastotestwhetheritispossibletoachieveanefficientandlong-term knockdownoftheTHexpressioninratsubstantianigra(SN)bycontinuousexpressionof shRNAconstructsfromanrAAV5vectorwithoutcausinganynonspecifictoxiceffectsinthe transducedcells.Forthispurpose,wegeneratedrAAV5vectorsexpressingtwodifferent knockdownconstructsandtheirscrambledcontrols.Aninitialsetof10siRNAwasdesigned accordingtotheTuschlrules.
11 UsinganexpressioncassettedrivenbytheH1promoter,the resultingsilencingefficacywastestedbyco-transfectionwiththeenhancedgreen fluorescenceprotein(GFP)-ratTHfusionprotein-expressingplasmidin293Tcells. ExpressionoftheGFP-ratTHfusionproteinwasmonitoredbyflowcytometryandthefinal twosequenceswereselectedformaximalsilencingefficacy.Theinvivoworkincludeda dose-responsestudyforrAAV5vectorsexpressingbothactiveshRNAvectors(shTH1and shTH2)andtheirscrambledcontrols(shTH1scrandshTH2scr).Tobeabletoidentifythe transducedcellsunambiguously,allrAAV5vectorsexpressedGFPdrivenbyasynthetic chickenβ-actinpromoter.Inaddition,aseparaterAAV5vectorcodingonlyfortheGFP markergenewasusedasanon-shRNAcontrolvector.Ourgoalwastodefineadosewindow thatwouldresultinanefficientknockdownwithoutcausingtoxicity.Thelevelofknockdown wasassessedinhistologicalspecimensbyquantifyingthenumberofnigralneurons expressingTH,whereasreductioninvesicularmonoaminetransporter-2(VMAT2)-expressingcellswasusedasameasureofnonspecifictoxicity. 11 gc/ml titers. Confocal microscopical images demonstrates labeling for the TH (green; panels a,e,i,m), VMAT2 (red; panels b,f,j,n) and the GFP (blue; c,g,k,o) proteins and the merged panels (d,h,l,p) on the (a-d) intact side, (e-h) rAAV5-shTH1, rAAV5-shTH1scr (i-l) or the (m-p) rAAV5-GFP vector injected sides. Note that both shTH1 and shTH1scr constructs also contain the GFP gene to allow for demonstration of transgene expression. rAAV5-shTH1 overexpression leads to a specific and efficient downregulation of the (e) TH protein, whereas in the rAAV5-shTH1scr or the rAAV5-GFP groups all three proteins are readily detectable giving the white color in the merged panels (l,p). The titers of vectors (genome copies) illustrated in this figure are rAAV5-GFP: 2.0 x 10
11
; rAAV5-shTH1: 1.8 x 10 11 , rAAV5-shTH1scr: 4.4 x 10
. Scale bar in p represents 100 µm and applies to all panels. , and the cresyl violet (c, f, i, l, o) stained specimens at the level of ventral midbrain. The cytoarchitectural integrity was maintained in animals treated with efficient dose of the viral preparations that did not lead to any toxicity (d-f for GFP, g-I for shTH1scr and j-l for shTH1 groups). There were no detectable differences between these specimens and the uninfected control side (a-c). On the other hand, injections of higher doses were associated with clearance of the neuronal cell layers within the (m) SN pars compacta, (n) activation of microglia and (o) hypercellularity suggesting a strong inflammatory response to toxicity. Note that the latter case is illustrated by a specimen from an animal treated with rAAV5-shTH1 vector but similar results were seen virtually all vectors at the toxic dose level. Scale bar in m represents 300μm in a, d, g, j and m, and 50 μm in all other panels, Abbreviations: cp, cerebral peduncle; SNc, substantia nigra pars compacta; SNr, substantia nigra pars reticulata. Figure 5 Biochemical alterations after rAAV5-shTH1 mediated TH knockdown. (a, b) DOPA accumulation was measured in the microdialysate after injection of 100mg/kg NSD-1015 at 9-12 weeks after the transduction. This assay provides a measure of the activity of TH enzyme in vivo. DOPA accumulation rate was significantly lower in shTH1 and 6-OHDA groups compared to the intact animals, whereas no significant difference was observed in shTH1scr group. Total DOPA synthesis measured over the 90 min sampling time in rAAV-shTH1 treated and 6-OHDA lesioned animals were significantly reduced as compared with the scrambled and intact controls (b). In a separate set of animals the striatal tissue homogenates were processed for in vitro enzyme activity. The results confirmed that TH activity was reduced by about 63% in shTH1 group and 70% in the 6-OHDA lesion group compared to the intact side. Whereas the scrambled controls did not differ from the intact controls. (c) AADC enzyme activity was similarly reduced in the 6-OHDA lesion group but remained unchanged in shTH1 and shTH1scr groups compared untreated animals, confirming the specificity of the knockdown (d). Statistical comparisons were performed using one-way ANOVA (b, F(3,17) = 24.37, p<0.0001; c, F(3,29) = 23.47, p<0.0001; d, F(3,29) = 9,11, p<0.0003), followed by Tukey post-hoc analysis. ⁺Different from intact control and shTH1scr groups. *Different from the all other groups. ¹¹ gc/ml rAAV5-shTH1.
forepaw use was reduced to 23% in the shTH1 group, whereas the expression of the shTH1scr construct had no effect. These rats were able to use both forepaws symmetrically as seen in the -triatal 6-OHDA lesion was included as a lesion-reference group, which showed a clear impairment in resulted in a complete recovery in the shTH1 group at already 90 minutes, which was maintained for at least 6 hours. The same dose of L-DOPA provided a minor change form (10% to 21%) in the 6-OHDA lesioned rats at 90 minutes. This effect was lost already at 180 minutes. *Different from the measures ANOVA, F(3,26) = 7.40, p<0.0001, followed by individual contrast post hoc analysis.
